In-vitro assessment of a PARI LC PLUS® nebuliser utilising a standard inhalation pattern compared to breathing profiles of 3 cyctic fibrosis (CF) patients (English)
- New search for: Jauernig, J.
- New search for: Jahn, D.
- New search for: Stempfle, P.
- New search for: Balcke, A.
- New search for: Keller, M.
- New search for: Aerosol Society
- New search for: Jauernig, J.
- New search for: Jahn, D.
- New search for: Stempfle, P.
- New search for: Balcke, A.
- New search for: Keller, M.
- New search for: Aerosol Society
In:
Drug delivery to the lungs
;
179-182
;
2001
-
ISBN:
- Conference paper / Print
-
Title:In-vitro assessment of a PARI LC PLUS® nebuliser utilising a standard inhalation pattern compared to breathing profiles of 3 cyctic fibrosis (CF) patients
-
Contributors:Jauernig, J. ( author ) / Jahn, D. ( author ) / Stempfle, P. ( author ) / Balcke, A. ( author ) / Keller, M. ( author ) / Aerosol Society
-
Conference:Meeting; 12th, Drug delivery to the lungs ; 2001 ; London
-
Published in:Drug delivery to the lungs ; 179-182
-
Publisher:
- New search for: Aerosol Society
-
Place of publication:Bristol
-
Publication date:2001-01-01
-
Size:4 pages
-
ISBN:
-
Type of media:Conference paper
-
Type of material:Print
-
Language:English
-
Keywords:
-
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents conference proceedings
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 7
-
Advances in treating systemic diseases with aerosolised medicineLaube, B. / Aerosol Society et al. | 2001
- 15
-
A comparison of the immune response exhibited following single dose administration of non-porous and porous poly(DL)lactide-co-glycolide microspheresCocks, E. / Alpar, H. O. / McKenzie, L. / Purewal, T. S. / Aerosol Society et al. | 2001
- 19
-
Microparticle transfer to systemic compartments and subsequent immunopotentiation following pulmonary deliveryEyles, J. E. / Bramwell, V. W. / Williamson, E. D. / Alpar, H. O. / Aerosol Society et al. | 2001
- 23
-
Patient individualized inhalation optimises peripheral lung depositionMullinger, B. / Meyer, T. / Sommerer, K. / Weber, N. / Beckmann, H. / Bernhardt, T. / Scheuch, G. / Aerosol Society et al. | 2001
- 27
-
Respiratory aerosol probe - A tool for inhalation therapy control of longitudinal studiesHaussermann, S. / Brand, P. / Meyer, T. / Scheuch, G. / Aerosol Society et al. | 2001
- 31
-
The in vitro assessment of aerosolised drug deposition using novel oropharyngeal modelsMasoud, O. / Martin, G. P. / Marriott, C. / Nichols, S. / Aerosol Society et al. | 2001
- 35
-
Comparison of the development of a pharmaceutical aerosol in USP and "Biological" throats using computational fluid dynamicsHarrington, L. / Versteeg, H. K. / Ehtezazi, T. / Horsfield, M. A. / Barry, P. W. / O Callaghan, C. / Aerosol Society et al. | 2001
- 39
-
Particle size measurement in aerosol formulationWashington, C. / Aerosol Society et al. | 2001
- 46
-
Characterization of sustained release inhaled Rifampin compared between two different coating methods: Pulsed laser deposition (PLD) and spray dryingCoowanitwong, I. / Kim, W.-S. / Craciun, V. / Kulvanich, P. / Singh, R. / Hughes, J. / Hochhaus, G. / Aerosol Society et al. | 2001
- 50
-
PulmoSphere® particle engineering - Technology development to pilot scale and commercial viabilityVenthoye, G. / Weers, J. / Tarara, T. / Aerosol Society et al. | 2001
- 54
-
Particle size measurement techniques for pharmaceutical device developmentZiegler, J. / Wachtel, H. / Aerosol Society et al. | 2001
- 58
-
Simultaneous analysis of respirable aerosols via laser diffraction and cascade impactionHolmes, C. / Kippax, P. / Newell, H. / Southall, J. / Ward, D. J. / Aerosol Society et al. | 2001
- 62
-
The use of laser diffraction for the assessment of the rate of drug particle detachment from carrier crystals in adhesive mixtures during inhalationde Boer, A. H. / Gjaltema, D. / Hagedoorn, P. / Witt, W. / de Goede, J. / Frijlink, H. W. / Aerosol Society et al. | 2001
- 66
-
Nozzle examination methods for the next generation pharmaceutical impactorRoberts, D. L. / Romay, F. J. / Marple, V. A. / Aerosol Society et al. | 2001
- 70
-
Advanced pulmonary systems: A novel high-performance formulation-integrated dry powder inhaler (FIDPI) for peptide and protein systemic drug deliveryStaniforth, J. N. / Braithwaite, P. / Ganderton, D. / Morton, D. A. V. / Wyber, J.-A. / Parry-Billings, M. / Patel, N. / Price, R. / Tservistas, M. / Aerosol Society et al. | 2001
- 74
-
Skye Dry™ for stabilization of metered dose inhaler suspension formulationsMueller-Walz, R. / Gilchrist, P. / Herzog, K. / Niederlaender, C. / Pignatelli, G. / Aerosol Society et al. | 2001
- 78
-
Aerosol generation using a dispersion mechanism based on powder flow characteristicsCrowder, T. M. / Hickey, A. J. / Aerosol Society et al. | 2001
- 79
-
Evaluation of pressurised metered dose inhalers (pMDIs) for pulmonary delivery of proteins and peptidesKoppenhagen, F. / Pritchard, Y. / Fulton, C. / Beynon, G. / Tilley, K. / McKenzie, L. / Oliver, M. J. / Aerosol Society et al. | 2001
- 83
-
Therapeutic Particle EngineeringEdwards, D. A. / Aerosol Society et al. | 2001
- 84
-
Surface characterisation of inhalation microparticles: Physical and chemical analysisEbbens, S. / Luk, S. Y. / Davies, M. C. / Roberts, C. J. / Patel, N. / Aerosol Society et al. | 2001
- 88
-
Recommendations to the FDA regarding the CMC draft guidances for MDIs and DPIs: The work of the ITFG/IPAC-RS tests and methods teamEvans, C. / Aerosol Society et al. | 2001
- 92
-
Test methods for inhalers to check performance under normal use and unintentional misusePurewal, T. / Aerosol Society et al. | 2001
- 99
-
Novel liquid formulation technologies as a tool to design the aerosol performance of nebulisers using an air jet (LC Plus®) or a vibrating membrane principle (E-Flow™)Keller, M. / Lintz, F.-C. / Walther, E. / Aerosol Society et al. | 2001
- 103
-
TouchSpray™ technology: Preliminary results from the in vitro evaluation of Insulin and AlbuminSmart, J. / Stang, R. / Halsall, I. / Chrystyn, H. / Aerosol Society et al. | 2001
- 107
-
The PARI e-Flow™: Tools in the development process of a new inhaler for topic and systemic pulmonary drug deliveryStangl, R. / Aerosol Society et al. | 2001
- 111
-
The consistent delivery valve: An improved valve for metered dose inhalersMahon, G. / Wilby, M. / Helm, S. / Balcombe, K. / Baron, C. / Fradley, G. / Aerosol Society et al. | 2001
- 115
-
Development of an in vitro dissolution-absorption model to evaluate the delivery of aerosolised drug from dry powder inhaler formulationsTee, S. K. / Forbes, B. / Larhrib, H. / Marriott, C. / Martin, G. P. / Aerosol Society et al. | 2001
- 119
-
PowderHale™: A novel high-performance dry powder inhaler formulation technology for targeted and systemic drug deliveryBegat, P. / Green, M. / Morton, D. A. V. / Whittock, A. / Staniforth, J. N. / Aerosol Society et al. | 2001
- 123
-
Particle design for dry powder inhalation systems: The influence of delivery device designParveen, Z. / Ghafoor, I. / Palakodaty, S. / Gilbert, D. J. / Walker, S. E. / Feeley, J. C. / Aerosol Society et al. | 2001
- 127
-
Potential of granulated lactose as a carrier in dry powder inhalationEllison, M. / Lambregts, D. / Dickhoff, B. H. J. / de Boer, A. H. / Frijlink, H. W. / Aerosol Society et al. | 2001
- 131
-
Poly (lactic-co-glycolic acid) microspheres as a means of drug delivery to the lung: The effect of process variables on particle sizeAl-Najar, M. A. / Martin, G. P. / Marriott, C. / Aerosol Society et al. | 2001
- 135
-
The modification of dry powder formulation performance by use of a novel nano-phase force control agentGanderton, D. / Morton, D. A. V. / Simpson, D. / Staniforth, J. N. / Aerosol Society et al. | 2001
- 139
-
Effect of inhalation flow rate on the dosing characteristics of a novel multi dose dry powder inhaler (DPI)Buttrum, M. E. / Dey, F. / Aerosol Society et al. | 2001
- 143
-
Measurement and setting of flow rates in pharmaceutical aerosol dispersion testingCox, R. / Versteeg, H. / Shott, M. J. / Aerosol Society et al. | 2001
- 147
-
Developing methods to demonstrate the pharmaceutical performance of inhaled therapeutic proteinsTilley, K. / Aerosol Society et al. | 2001
- 148
-
The influence of actuator charge on the particle size distribution and plume characteristics of a pMDI productButler, M. / Derbyshire, H. M. / Boyd, G. / Suggett, J. / Aerosol Society et al. | 2001
- 152
-
Guidance on materials compatibility for the manufacture of pharmaceutical aerosols using HFAs (HFA-MDIs)Pittroff, M. / Pischtiak, A. / Aerosol Society et al. | 2001
- 154
-
A new valved holding chamber (VHC) with positive expiratory pressureMitchell, J. P. / Nagel, M. W. / Doyle, C. C. / Bates, S. L. / Wiersema, K. J. / Engelbreth, D. K. / Aerosol Society et al. | 2001
- 157
-
Comparison of valved holding chamber (VHC) performance with HFA-and CFC-formulated Ventolin®Mitchell, J. P. / Nagel, M. W. / Doyle, C. C. / Bates, S. L. / Wiersema, K. J. / Schmidt, J. N. / Aerosol Society et al. | 2001
- 161
-
A novel approach to produce versatile pMDI container closureBradley, L. / Aerosol Society et al. | 2001
- 162
-
Influence of HFA formulations on Spraymister™ valvesVelasco, V. / Aerosol Society et al. | 2001
- 163
-
In vitro evaluation of holding chambers for delivery of inhaled medications to the mechanically ventilated patientMitchell, J. P. / Nagel, M. W. / Doyle, C. C. / Bates, S. L. / Aerosol Society et al. | 2001
- 167
-
Deposition of therapeutic aerosols in the lung periphery by controlled inhalationHaussermann, S. / Brand, P. / Meyer, T. / Scheuch, G. / Aerosol Society et al. | 2001
- 171
-
Evaluation of an optimal device for peripheral deposition in patients with lung emphysemaSommerer, K. / Meyer, T. / Brand, P. / Mullinger, B. / Pohner, A. / Weber, N. / Beckmann, H. / Maas-Enriquez, M. / Scheuch, G. / Aerosol Society et al. | 2001
- 175
-
Adenovirus-mediated gene transfer to respiraory epithelial cells: No inhibition by mucus hypersecretionForbes, B. / Hashmi, N. / Lansley, A. B. / Martin, G. P. / Aerosol Society et al. | 2001
- 179
-
In-vitro assessment of a PARI LC PLUS® nebuliser utilising a standard inhalation pattern compared to breathing profiles of 3 cyctic fibrosis (CF) patientsJauernig, J. / Jahn, D. / Stempfle, P. / Balcke, A. / Keller, M. / Aerosol Society et al. | 2001
- 183
-
Effect of operating pressure, drug concentration and volume fill on the nebulisation efficiency of jet nebulisersBalcke, A. / Jahn, D. / Stempfle, P. / Schuschnig, U. / Keller, M. / Aerosol Society et al. | 2001
- 187
-
Smoothing the stepped structure of the upper airway reconstructed from the rapid MR scansEhtezazi, T. / Horsfield, M. A. / Barry, P. W. / O Callaghan, C. / Aerosol Society et al. | 2001
- 191
-
A potential mucosal adjuvant for nasal delivery of vaccines: Zinc-Chitosan particlesMcHugh, C. J. / Somavarapu, S. / Singh, J. / Bramwell, V. / Alpar, H. O. / Aerosol Society et al. | 2001